@article{oai:dmu.repo.nii.ac.jp:00002295,
 author = {Muto, Tetsuya and Machida, Shigeki},
 issue = {1},
 journal = {Dokkyo Journal of Medical Sciences},
 month = {Mar},
 note = {Purpose：S-1 is an oral anticancer drug containing tegafur, a prodrug of 5-fluorouracil（5-FU）. We present a patient who experienced corneal perforation that appeared to be caused by S-1 administration．
Case：A 67-year-old woman was presented to our hospital because of corneal perforation in her left eye. She had been administrated S-1 for 17 months from gastroenterological surgeon at another hospital for treating pancreatic cancer. The best-corrected visual acuity was 0.4 in the right eye and 0.1 in the left eye at the initial visit. Convoluted subepithelial opacity was present in the cornea of the right eye, and corneal perforation was observed in the left eye. Anterior chamber formation was very poor, and iris incarceration was present in the left eye. Although anterior chamber formation was attempted with the use of soft contact lens wear, the condition remained unchanged. We requested to discontinue S-1 administration to gastroenterological surgery at another hospital. The patient was presented to the department of ophthalmology at another hospital because her eye condition and pancreatic cancer could be treated at the same institution.
Conclusion：Patients treated with S-1 should be carefully followed up for ocular complications because corneal perforation may occur.},
 pages = {35--37},
 title = {Corneal Perforation Associated with the Oral Anticancer Drug S-1：A Case Report},
 volume = {47},
 year = {2020}
}